View Post

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Skarzynski From: curetoday.com For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated promising activity in patients with recurrent ovarian cancer or advanced breast cancer. In the JAMA Oncology study, the …

View Post

Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

In Clinical Trials by Barbara Jacoby

From: ptcommunity.com Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of …

View Post

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

In Clinical Trials by Barbara Jacoby

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favorable safety profile in early stage cervical cancer- -Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 …